Literature DB >> 9784572

Protection against exotoxin A (ETA) and Pseudomonas aeruginosa infection in mice with ETA-specific antipeptide antibodies.

H S El-Zaim1, A K Chopra, J W Peterson, M L Vasil, J P Heggers.   

Abstract

Pseudomonas aeruginosa is an opportunistic pathogen that causes serious and sometimes fatal infections in the compromised host, especially in patients with major trauma or thermal injuries. Exotoxin A (ETA) is the major and most lethal virulence factor produced by this ubiquitous microorganism. In a recent study (H. S. Elzaim, A. K. Chopra, J. W. Peterson, R. Goodheart, and J. P. Heggers, Infect. Immun. 66:2170-2179, 1998), we identified two major epitopes, one within the translocation domain (amino acid [aa] residues 289 to 333) of ETA and another within the enzymatic domain (aa 610 to 638), by using a panel of antipeptide antibodies. Synthetic peptides representing these two epitopes induced ETA-specific antibodies which were able to abrogate the cytotoxic activity of ETA, as measured by incorporation of [3H]leucine into 3T3 fibroblasts. In the present study, these antibodies were tested for the ability to provide protection against ETA and infection with a toxin-producing strain of P. aeruginosa in a mouse model. Antibodies to either of the synthetic peptides conferred protection against ETA. Also, when used for immunization, both peptides induced active immunity to ETA in mice. Antibodies to the peptide representing a region within the enzymatic domain of ETA, in combination with the antibiotic amikacin, enhanced the survival of mice infected with a toxin-producing strain of P. aeruginosa. Thus, antipeptide antibodies specific for ETA might be paired with antibiotic treatment for passive immunization of patients suffering from P. aeruginosa infection.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9784572      PMCID: PMC108698          DOI: 10.1128/IAI.66.11.5551-5554.1998

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.609


  22 in total

1.  Pseudomonas exotoxin shock. A preliminary report of studies in dogs.

Authors:  M Atik; P V Liu; B A Hanson; S Amini; C F Rosenberg
Journal:  JAMA       Date:  1968-07-15       Impact factor: 56.272

2.  Functionally distinct monoclonal antibodies reactive with enzymatically active and binding domains of Pseudomonas aeruginosa toxin A.

Authors:  J K Chia; M Pollack; D Avigan; S Steinbach
Journal:  Infect Immun       Date:  1986-06       Impact factor: 3.609

3.  Structure of exotoxin A of Pseudomonas aeruginosa at 3.0-Angstrom resolution.

Authors:  V S Allured; R J Collier; S F Carroll; D B McKay
Journal:  Proc Natl Acad Sci U S A       Date:  1986-03       Impact factor: 12.779

4.  Functional domains of Pseudomonas exotoxin identified by deletion analysis of the gene expressed in E. coli.

Authors:  J Hwang; D J Fitzgerald; S Adhya; I Pastan
Journal:  Cell       Date:  1987-01-16       Impact factor: 66.850

5.  Primate antibody response to immunotoxin: serological and computer-aided analysis of epitopes on a truncated form of Pseudomonas exotoxin.

Authors:  D M Roscoe; S H Jung; I Benhar; L Pai; B K Lee; I Pastan
Journal:  Infect Immun       Date:  1994-11       Impact factor: 3.609

6.  Generation of neutralizing antipeptide antibodies to the enzymatic domain of Pseudomonas aeruginosa exotoxin A.

Authors:  H S Elzaim; A K Chopra; J W Peterson; R Goodheart; J P Heggers
Journal:  Infect Immun       Date:  1998-05       Impact factor: 3.609

7.  Characterization of monoclonal antibody B7, which neutralizes the cytotoxicity of Pseudomonas aeruginosa exotoxin A.

Authors:  H F Shang; M L Yeh; C P Lin; J Hwang
Journal:  Clin Diagn Lab Immunol       Date:  1996-11

8.  Cloning, nucleotide sequence, and expression in Escherichia coli of the exotoxin A structural gene of Pseudomonas aeruginosa.

Authors:  G L Gray; D H Smith; J S Baldridge; R N Harkins; M L Vasil; E Y Chen; H L Heyneker
Journal:  Proc Natl Acad Sci U S A       Date:  1984-05       Impact factor: 12.779

Review 9.  The role of exotoxin A in pseudomonas disease and immunity.

Authors:  M Pollack
Journal:  Rev Infect Dis       Date:  1983 Nov-Dec

10.  Protective activity of anti-exotoxin A monoclonal antibody against mice infected with toxin-producing Pseudomonas aeruginosa.

Authors:  T Kohzuki; Y Eguchi; M Kato; K Irie; H Ohtsuka; A Higuchi; H Noguchi
Journal:  J Infect Dis       Date:  1993-01       Impact factor: 7.759

View more
  10 in total

1.  Immunization with 3-oxododecanoyl-L-homoserine lactone-r-PcrV conjugate enhances survival of mice against lethal burn infections caused by Pseudomonas aeruginosa.

Authors:  Isar Dejban Golpasha; Seyed Fazlollah Mousavi; Parviz Owlia; Seyed Davar Siadat; Shiva Irani
Journal:  Bosn J Basic Med Sci       Date:  2015-05-25       Impact factor: 3.363

2.  Efficacy of locally delivered polyclonal immunoglobulin against Pseudomonas aeruginosa peritonitis in a murine model.

Authors:  N A Barekzi; K A Poelstra; A G Felts; I A Rojas; J B Slunt; D W Grainger
Journal:  Antimicrob Agents Chemother       Date:  1999-07       Impact factor: 5.191

Review 3.  Pseudomonas aeruginosa virulence and therapy: evolving translational strategies.

Authors:  Jeffrey L Veesenmeyer; Alan R Hauser; Thiago Lisboa; Jordi Rello
Journal:  Crit Care Med       Date:  2009-05       Impact factor: 7.598

4.  Locally delivered polyclonal antibodies potentiate intravenous antibiotic efficacy against gram-negative infections.

Authors:  Nazir A Barekzi; Adrian G Felts; Kornelis A Poelstra; Jeffrey B Slunt; David W Grainger
Journal:  Pharm Res       Date:  2002-12       Impact factor: 4.200

5.  Dual-function vaccine for Pseudomonas aeruginosa: characterization of chimeric exotoxin A-pilin protein.

Authors:  R Hertle; R Mrsny; D J Fitzgerald
Journal:  Infect Immun       Date:  2001-11       Impact factor: 3.609

6.  A dominant-negative approach that prevents diphthamide formation confers resistance to Pseudomonas exotoxin A and diphtheria toxin.

Authors:  Vincent Roy; Karim Ghani; Manuel Caruso
Journal:  PLoS One       Date:  2010-12-23       Impact factor: 3.752

7.  Intranasal immunization strategy to impede pilin-mediated binding of Pseudomonas aeruginosa to airway epithelial cells.

Authors:  Jennifer C Hsieh; Doris M Tham; Weijun Feng; Fan Huang; Selamawit Embaie; Keyi Liu; Deborah Dean; Ralf Hertle; David J Fitzgerald; Randall J Mrsny
Journal:  Infect Immun       Date:  2005-11       Impact factor: 3.609

Review 8.  Alternative pre-approved and novel therapies for the treatment of anthrax.

Authors:  Breanne M Head; Ethan Rubinstein; Adrienne F A Meyers
Journal:  BMC Infect Dis       Date:  2016-11-03       Impact factor: 3.090

9.  Active immunization using exotoxin A confers protection against Pseudomonas aeruginosa infection in a mouse burn model.

Authors:  Ali Manafi; Jamshid Kohanteb; Davood Mehrabani; Aziz Japoni; Masoud Amini; Mohsen Naghmachi; Ahmad Hosseinzadeh Zaghi; Nazanin Khalili
Journal:  BMC Microbiol       Date:  2009-02-01       Impact factor: 4.465

10.  Pseudomonas aeruginosa AlgR Phosphorylation Status Differentially Regulates Pyocyanin and Pyoverdine Production.

Authors:  Alexander S Little; Yuta Okkotsu; Alexandria A Reinhart; F Heath Damron; Mariette Barbier; Brandon Barrett; Amanda G Oglesby-Sherrouse; Joanna B Goldberg; William L Cody; Michael J Schurr; Michael L Vasil; Michael J Schurr
Journal:  mBio       Date:  2018-01-30       Impact factor: 7.867

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.